Business Wire

MILREM-ROBOTICS

14.9.2021 09:02:12 CEST | Business Wire | Press release

Share
Milrem Robotics to Develop the Nordic Robotic Wingman With Kongsberg Defence & Aerospace

The leading European robotics and autonomous systems developer Milrem Robotics is to develop a new Robotic Combat Vehicle (RCV) named Nordic Robotic Wingman in cooperation with the leading technology and defence supplier, Kongsberg Defence & Aerospace (KONGSBERG).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005044/en/

The Nordic Robotic Wingman will be based on Milrem Robotics’ state of the art Type-X RCV and KONGSBERG’s latest and best PROTECTOR Remote Turrets (RT) that will be chosen specifically to meet the particular needs of various end-users.

The first Nordic Robotic Wingman concept will be exhibited at DSEI 2021 in London.

“Milrem Robotics and KONGSBERG have agreed to jointly continue the development of the Type-X RCV by integrating KONGSBERG’s systems to address the requirements of many countries interested in this type of technology, especially the Nordics and Western Europe, but also the US,” said Sverker Svärdby, Managing Director of Milrem Robotics’ Sweden. “Combining our knowledge of robotic combat vehicles and KONGSBERG’s wide range of systems and extensive expertise in defence systems development, we are capable of providing world-class systems based on customer needs,” Svärdby added.

The Type-X provides equal or overmatching firepower and tactical usage to a unit equipped with Infantry Fighting vehicles and gives mechanized units the means to breach enemy defensive positions with minimal risk to own troops. It can be fitted with a cannon up to 50 mm, anti-tank missiles and a tethered drone for continuous situational awareness.

“KONGSBERG has a family of unmanned PROTECTOR Remote Weapon Systems, ranging from the smallest RS2 Remote Weapon Station to the true Infantry Fighting Vehicle turret RT60 with Anti-Tank Guided Missile capability. The systems have a common software baseline, are easy to integrate and provide proven capabilities for the warfighter. KONGSBERG’s solution provides the operator with situational awareness and a safe and secure network-based fire control that is fielded with the Norwegian Army and in delivery to the US Army’s Robotic Combat Vehicle program,” said Arne Gjennestad, Vice President of Marketing & Sales, KONGSBERG.

Milrem Robotics’ Type-X is equipped with intelligent functions such as follow-me, waypoint navigation and obstacle detection with Artificial Intelligence being part of the algorithms. With the Type-X Milrem Robotics also introduces a feature called Indirect Drive that allows remote controlled operations on higher speeds.

Milrem Robotics is the European leading robotics and autonomous systems developer and systems integrator with offices in Estonia, Sweden, Finland and shortly in the Netherlands.

The company leads the iMUGS Consortium that was awarded 30,6 MEUR from the European Commission’s European Defence Industrial Development Programme (EDIDP) to develop a European standardized unmanned ground system (UGS).

Kongsberg Defence & Aerospace is a leading supplier of defence products and systems for command and control, surveillance, space, tactical communications, remote weapon stations and missiles, as well as advanced composites, engineering products and repair and overhaul services for aircraft and helicopters.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye